+

WO2008040002A3 - Methods, compositions and articles of manufacture for hif modulating compounds - Google Patents

Methods, compositions and articles of manufacture for hif modulating compounds Download PDF

Info

Publication number
WO2008040002A3
WO2008040002A3 PCT/US2007/079948 US2007079948W WO2008040002A3 WO 2008040002 A3 WO2008040002 A3 WO 2008040002A3 US 2007079948 W US2007079948 W US 2007079948W WO 2008040002 A3 WO2008040002 A3 WO 2008040002A3
Authority
WO
WIPO (PCT)
Prior art keywords
hif
methods
articles
compositions
manufacture
Prior art date
Application number
PCT/US2007/079948
Other languages
French (fr)
Other versions
WO2008040002A2 (en
WO2008040002A9 (en
Inventor
Mark B Roth
Mark Budde
Original Assignee
Hutchinson Fred Cancer Res
Mark B Roth
Mark Budde
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchinson Fred Cancer Res, Mark B Roth, Mark Budde filed Critical Hutchinson Fred Cancer Res
Publication of WO2008040002A2 publication Critical patent/WO2008040002A2/en
Publication of WO2008040002A9 publication Critical patent/WO2008040002A9/en
Publication of WO2008040002A3 publication Critical patent/WO2008040002A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Surgery (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention generally relates to the modulation of hypoxia- inducible factor (HIF) using the compounds and methods disclosed herein. These compounds and methods can be applied to the prevention, pretreatment, and/or treatment of conditions or states associated with HIF, such as hypoxia- and ischemia-related conditions and the induction of stasis.
PCT/US2007/079948 2006-09-28 2007-09-28 Methods, compositions and articles of manufacture for hif modulating compounds WO2008040002A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82733706P 2006-09-28 2006-09-28
US60/827,337 2006-09-28

Publications (3)

Publication Number Publication Date
WO2008040002A2 WO2008040002A2 (en) 2008-04-03
WO2008040002A9 WO2008040002A9 (en) 2009-04-16
WO2008040002A3 true WO2008040002A3 (en) 2009-07-09

Family

ID=39032331

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/079948 WO2008040002A2 (en) 2006-09-28 2007-09-28 Methods, compositions and articles of manufacture for hif modulating compounds

Country Status (2)

Country Link
US (2) US20090011051A1 (en)
WO (1) WO2008040002A2 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6855510B2 (en) * 2001-03-20 2005-02-15 Dana Farber Cancer Institute, Inc. Pharmaceuticals and methods for treating hypoxia and screening methods therefor
JO2934B1 (en) 2006-06-23 2015-09-15 سميث كلاين بيتشام كوربوريشن Prolyl Hydroxylase Inhibitors
CA2672652C (en) 2006-12-18 2012-04-17 Amgen Inc. Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
AU2007334323B2 (en) 2006-12-18 2011-03-10 Amgen Inc. Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
TW200845991A (en) 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: hydroxylase inhibitors
JP2010524942A (en) 2007-04-18 2010-07-22 アムジエン・インコーポレーテツド Quinolone and azaquinolone that inhibit prolyl hydroxylase
EP2155680B1 (en) 2007-04-18 2013-12-04 Amgen, Inc Indanone derivatives that inhibit prolyl hydroxylase
WO2008137084A2 (en) 2007-05-04 2008-11-13 Amgen Inc. Diazaquinolones that inhibit prolyl hydroxylase activity
WO2008137060A1 (en) 2007-05-04 2008-11-13 Amgen Inc. Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity
US20100031892A1 (en) * 2008-07-07 2010-02-11 Ilyin Ilya Y Method for storage of live crustaceans
WO2010005959A1 (en) 2008-07-07 2010-01-14 Rich Products Corporation Method for treatment and storage of platelets
KR100976548B1 (en) * 2008-09-12 2010-08-17 김희구 Herbal pads with controlled release of medicinal ingredients and methods for preparing the same
US8277781B2 (en) * 2009-03-13 2012-10-02 Luitpold Pharmaceuticals, Inc. Device for intranasal administration
US8551454B2 (en) * 2009-03-13 2013-10-08 Luitpold Pharmaceuticals, Inc. Device for intranasal administration
US10980752B2 (en) 2009-09-14 2021-04-20 Bm Biotechnology Co., Ltd. Device for herbal medicine in which release of medicinal ingredient can be controlled, and manufacturing method thereof
WO2012037212A1 (en) * 2010-09-14 2012-03-22 Dana-Farber Cancer Institute, Inc. Prolyl hydroxylase inhibitors as radiation mitigators and radiation protectors
RU2690450C2 (en) 2011-09-26 2019-06-03 РИЧ ТЕКНОЛОДЖИЗ ХОЛДИНГ КОМПАНИ, ЭлЭлСи Thrombocyte preservation method
WO2013177478A2 (en) * 2012-05-24 2013-11-28 Glaxosmithkline Intellectual Property (No.2) Limited Treatment method
US9820981B2 (en) 2013-12-19 2017-11-21 The Cleveland Clinic Foundation Treatment of retinopathy of prematurity (ROP)
ES2987484T3 (en) 2014-02-10 2024-11-15 Fred Hutchinson Cancer Center Treatment of heart attack and ischemic injury with sodium iodide
US10359743B2 (en) * 2014-11-25 2019-07-23 Applied Materials, Inc. Substrate processing systems, apparatus, and methods with substrate carrier and purge chamber environmental controls
CN106146395B (en) * 2015-03-27 2019-01-01 沈阳三生制药有限责任公司 3- hydroxypyridine compound, preparation method and its pharmaceutical applications
WO2017027810A2 (en) * 2015-08-12 2017-02-16 The General Hospital Corporation Compositions and methods that promote hypoxia or the hypoxia response for treatment and prevention of mitochondrial dysfunction and oxidative stress disorders
WO2017059427A1 (en) * 2015-10-02 2017-04-06 Children's National Medical Center Methods for monitoring and determining the prognosis of strokes, peripheral vascular disease, shock, and sickle cell disease and its complications
EP3383415B1 (en) 2015-12-01 2021-03-31 Cornell University Use of mitochondrial iron chelators for treatment of chronic obstructive pulmonary disease
CN107417605A (en) * 2017-08-02 2017-12-01 江苏艾立康药业股份有限公司 Act on the pyridine derivative compound of prolyl hydroxylase
JP7386162B2 (en) * 2017-12-20 2023-11-24 フィジーン、エルエルシー Enhancement of regenerative activity of fibroblasts
US12089930B2 (en) 2018-03-05 2024-09-17 Marquette University Method and apparatus for non-invasive hemoglobin level prediction
WO2019222362A1 (en) * 2018-05-15 2019-11-21 Duke University Compositions and methods for preventing and/or reducing ischemia after surgical incisions
US20210113524A1 (en) * 2018-05-31 2021-04-22 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods of treating myeloproliferative disorders
CN111001016B (en) * 2019-12-20 2022-06-17 中国人民解放军陆军军医大学 Detection method for inhibiting DR5 spermatogenesis reduction under hypoxia through VHA
AR123243A1 (en) * 2020-08-14 2022-11-09 Akebia Therapeutics Inc PHD INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE
CN112618697B (en) * 2020-12-22 2021-10-01 浙江师范大学 A kind of aquatic product cryoprotectant and use thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003053997A2 (en) * 2001-12-06 2003-07-03 Fibrogen, Inc. Methods of increasing endogenous erythropoietin (epo)
US20040254215A1 (en) * 2003-06-06 2004-12-16 Fibrogen, Inc. Novel nitrogen-containing heteroaryl compounds and methods of use thereof
WO2005039291A2 (en) * 2003-10-22 2005-05-06 Fred Hutchinson Cancer Research Center Methods, compositions and devices for inducing stasis in cells
US20050136125A1 (en) * 2003-10-22 2005-06-23 Roth Mark B. Methods, compositions and devices for inducing stasis in cells, tissues, organs, and organisms
US20050170019A1 (en) * 2003-10-22 2005-08-04 Fred Hutchinson Cancer Research Center Methods, compositions and devices for inducing stasis in cells
WO2006113914A2 (en) * 2005-04-20 2006-10-26 Fred Hutchinson Cancer Research Center Methods, compositions and articles of manufacture for enhancing survivability of cells, tissues, organs, and organisms
WO2007124447A2 (en) * 2006-04-20 2007-11-01 Fred Hutchinson Cancer Research Center Use of chalcogenides for treating shock and other adverse conditions

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003053997A2 (en) * 2001-12-06 2003-07-03 Fibrogen, Inc. Methods of increasing endogenous erythropoietin (epo)
US20040254215A1 (en) * 2003-06-06 2004-12-16 Fibrogen, Inc. Novel nitrogen-containing heteroaryl compounds and methods of use thereof
WO2005039291A2 (en) * 2003-10-22 2005-05-06 Fred Hutchinson Cancer Research Center Methods, compositions and devices for inducing stasis in cells
US20050136125A1 (en) * 2003-10-22 2005-06-23 Roth Mark B. Methods, compositions and devices for inducing stasis in cells, tissues, organs, and organisms
US20050147692A1 (en) * 2003-10-22 2005-07-07 Fred Hutchinson Cancer Research Center Methods, compositions and devices for inducing stasis in tissues and organs
US20050170019A1 (en) * 2003-10-22 2005-08-04 Fred Hutchinson Cancer Research Center Methods, compositions and devices for inducing stasis in cells
WO2006113914A2 (en) * 2005-04-20 2006-10-26 Fred Hutchinson Cancer Research Center Methods, compositions and articles of manufacture for enhancing survivability of cells, tissues, organs, and organisms
WO2007124447A2 (en) * 2006-04-20 2007-11-01 Fred Hutchinson Cancer Research Center Use of chalcogenides for treating shock and other adverse conditions

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BERNHARDT WANJA M ET AL: "Preconditional activation of hypoxia-inducible factors ameliorates ischemic acute renal failure", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, vol. 17, no. 7, July 2006 (2006-07-01), pages 1970 - 1978, XP002470633, ISSN: 1046-6673 *
KOSHIJI MINORI ET AL: "HIF-1alpha induces cell cycle arrest by functionally counteracting Myc", EMBO (EUROPEAN MOLECULAR BIOLOGY ORGANIZATION) JOURNAL, vol. 23, no. 9, 5 May 2004 (2004-05-05), pages 1949 - 1956, XP002472242, ISSN: 0261-4189 *
METZEN ERIC ET AL: "Nitric oxide impairs normoxic degradation of HIF-1alpha by inhibition of prolyl hydroxylases.", MOLECULAR BIOLOGY OF THE CELL, vol. 14, no. 8, August 2003 (2003-08-01), pages 3470 - 3481, XP002470634, ISSN: 1059-1524 *
NYSTUL T G ET AL: "Carbon monoxide-induced suspended animation protects against hypoxic damage in Caenorhabditis elegans", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 101, no. 24, 15 June 2004 (2004-06-15), pages 9133 - 9136, XP002319272, ISSN: 0027-8424 *
TEODORO R O ET AL: "Nitric oxide-induced suspended animation promotes survival during hypoxia", EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 22, no. 3, 3 February 2003 (2003-02-03), pages 580 - 587, XP002319271, ISSN: 0261-4189 *

Also Published As

Publication number Publication date
WO2008040002A2 (en) 2008-04-03
US20090011051A1 (en) 2009-01-08
US20120282353A1 (en) 2012-11-08
WO2008040002A9 (en) 2009-04-16

Similar Documents

Publication Publication Date Title
WO2008040002A3 (en) Methods, compositions and articles of manufacture for hif modulating compounds
MX2010010209A (en) Substituted 4-hydroxypyrimidine-5-carboxamides.
WO2010062377A3 (en) Methods and compositions for the detection and treatment of preeclampsia
WO2008067219A3 (en) Quinazolinone modulators of tgr5
WO2009117421A3 (en) Heterocyclic modulators of gpr119 for treatment of disease
WO2009111676A8 (en) Boron-containing small molecules as anti-inflammatory agents
AU2016204376A1 (en) MicroRNA-based methods and compositions for the diagnosis and treatment of ovarian cancer
WO2007090068A3 (en) Cyanoisoquinoline compounds that stabilize hypoxia inducible factor (hif)
WO2008033562A3 (en) Kinase inhibitor compounds
WO2007092622A3 (en) Compositions and methods for treating bone
WO2009126934A3 (en) Detection and tratment of pancreatic, ovarian and other cancers
WO2009134380A8 (en) Super fast-acting insulin compositions
WO2008024304A3 (en) Compounds for treatment of proliferative disorders
WO2007057768A3 (en) Sulfonyl derivatives
WO2011091366A3 (en) Methods of treating or preventing periodontitis and diseases associated with periodontitis
WO2010138820A3 (en) N,n-diarylurea compounds and n,n'-diarylthiourea compounds as inhibitors of translation initiation
WO2010045345A3 (en) Treatment method
WO2006122156A3 (en) Compounds for modulating trpv3 function
WO2007056124A3 (en) Compounds for modulating trpv3 function
WO2008128072A3 (en) Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders
WO2009117676A3 (en) Novel piperidine derivatives as inhibitors of stearoyl-coa desaturase
WO2007101864A3 (en) Compounds that modulate ppar activity, their preparation and use
WO2010059317A3 (en) Separation process
WO2012170807A3 (en) Anti-pseudomonas psl binding molecules and uses thereof
WO2010042636A3 (en) Telomerase inhibitors and methods of use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07843518

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07843518

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载